Bayer (BAYRY) announced that the FDA has accepted the company’s supplemental new drug application, or sNDA, for the oral androgen receptor inhibitor, or ARi, Nubeqa in combination with androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer. Nubeqa is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BAYRY:
- Bayer price target lowered to EUR 22 from EUR 28 at Berenberg
- Cytokinetics partnership demonstrates value of aficamten, says JMP Securities
- Cytokinetics, Bayer enter collaboration and license pact for aficamten in Japan
- Bayer price target lowered to EUR 30 from EUR 35 at Morgan Stanley
- Bayer price target lowered to EUR 25 from EUR 34 at JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
